(S)-2-[(S)-[(2S,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid isopropyl ester | 1443648-67-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-[(S)-[(2S,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid isopropyl ester
• 英文别名: isopropyl ((S)-(((2S,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,4-difluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)-L-alaninate；propan-2-yl (2S)-2-[[[(2S,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-2,4-difluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]propanoate
• CAS: 1443648-67-6
• 化学式: C₂₆H₃₀F₂N₃O₉P
• 分子量: 597.509
• InChiKey: HJGQHTBMGRNGFC-UZEXBNKTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  41
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  153
• 氢给体数：
  3
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  (2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,4-difluor-O-2-(iodomethyl)-4-methyl-tetrahydrofuran-3-yl-benzoate 在 18-冠醚-6 、 叔丁基氯化镁 、 氨 作用下， 以 四氢呋喃 、 甲醇 、 二甲基亚砜 为溶剂， 反应 22.25h， 生成 (S)-2-[(R)-[(2S,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid isopropyl ester 、 (S)-2-[(S)-[(2S,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid isopropyl ester
  参考文献：
  名称：

  [EN] 2',4'-DIFLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
  [FR] DÉRIVÉS DE NUCLÉOSIDE SUBSTITUÉ 2',4'-DIFLUORO-2'-MÉTHYLE EN TANT QU'INHIBITEURS DE LA RÉPLICATION DE L'ARN DU VHC (VIRUS DE L'HÉPATITE C)

  摘要：

  本公开涉及公式（I）的化合物。还公开了包含公式（I）化合物的药物组合物，以及利用公式（I）化合物和/或包含公式（I）化合物的组合物治疗HCV的方法。

  公开号：

  WO2013092481A1

文献信息

• 2'-4'-DIFLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150004135A1

  公开（公告）日：2015-01-01

  The present disclosure relates to compounds of Formula (I): Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of using the compounds of Formula (I) and/or compositions comprising the compounds of Formula (I) for the treatment of HCV.

  本公开涉及化合物(I)的公式，还公开了包含化合物(I)的药物组成物、使用化合物(I)和/或组成物(I)的方法来治疗HCV的方法。
• 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
  申请人：Riboscience LLC

  公开号：US10682369B2

  公开（公告）日：2020-06-16

  Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.

  式 I 的胞苷核苷类似物（其中变量如本文所述）与式 II 的尿苷核苷类似物（其中变量如本文所述）的组合、 可产生抑制 HCV 聚合酶的协同效应。
• 2',4'-DIFLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2794629A1

  公开（公告）日：2014-10-29
• 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
  申请人：Riboscience LLC

  公开号：US20180200280A1

  公开（公告）日：2018-07-19

  Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.
• 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
  申请人：Riboscience LLC

  公开号：US20190231804A1

  公开（公告）日：2019-08-01

  Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.